HomeNews & Events

News & Events



Congratulations! TOT BIOPHARM's CDMO partner Bioray’s application for clinical trial of BRY812 injection, a Class 1 new drug was accepted

Bioray, TOT BIOPHARMs CDMO partner, announced that its application for clinical trials of BRY812 injection, a class 1 innovative biological product independently developed by itself, has been accepted by NMPA. BRY812 is a novel antibody-drug conjugate (AD

Congratulations! TOT BIOPHARM’s CDMO partner MediLink Therapeutics YL202 clinical trial application received default approval from the FDA

Recently, TOT BIOPHARM’s CDMO partner, MediLink Therapeutics, announced that its self-developed innovative antibody - drug conjugates (ADC) YL202 has received default approval from the FDA to conduct clinical trials for the treatment of advanced solid tum

Delivered ahead of schedule! TOT BIOPHARM Empowers Commercial Manufacture of COVID-19 Neutralizing Antibody

TOT BIOPHARM (Stock code: 1875.HK) announced that the CDMO service for commercial scale-up and manufacture of COVID-19 specific neutralizing antibody injection (JMB2002) for its partner Jemincare has completed in mid-August, one and a half months ahead of

TOT BIOPHARM and BrightGene Enter Into Strategic Partnership To Strengthen One-stop CDMO Service Platform for ADC

On July 19, TOT BIOPHARM (1875.HK) and BrightGene (688166.SH) jointly announced that the two companies will develop a strategic collaboration for Antibody-Drug Conjugates (ADC) CDMO services to facilitate the development and commercialization of innovativ